Multiple Sclerosis Clinical Trial

RELAXaHEAD for Headache Patients (Phase II)

Summary

The goal of this research is to assess the utility of smartphone-based progressive muscle relaxation (PMR) for the treatment of migraine and sleep. While there are many commercially available electronic diary and mind-body intervention apps for headache, there is little data showing their efficacy. RELAXaHEAD app incorporates the electronic PMR that was successfully used in an earlier epilepsy study and beta tested with headache specialist and migraine patient input. It also is an electric headache diary. The app has been studied and findings have been reported in multiple peer reviewed publications. Also, the app has been updated based on prior feedback from the studies. Now, this 2-arm randomized controlled study will evaluate the feasibility and acceptability of RELAXaHEAD for use with patients with migraine and comorbid insomnia. . One arm will be the RELAX group (the RELAXaHEAD app) and the other arm will be a monitored usual care (MUC) group (this group receives standard of care and uses the electronic daily symptom reporting diary). The goals are to assess the feasibility and adherence of the RELAX intervention in persons with migraine and insomnia (Aim 1) and to gather exploratory data on the effects of the RELAX intervention on headache and sleep related outcome measures (Aim 2).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age 18-80 years (age 18-65 in urgent care);
Meets migraine criteria based on the International Classification of Headache Disorders (ICHD) criteria;
Migraine Disability Assessment (MIDAS) score >5. 4+ headache days a month OR; meets chronic post- traumatic headache (PTH) criteria based on International Classification of Headache Disorders (ICHD) criteria, is 3-12 months post-injury, and there are 4+ headache days a month.
Scoring > or = 15 on the ISI.

Exclusion Criteria:

Patients who have had Cognitive Behavioral Therapy, Biofeedback, or other Relaxation Therapy in the past year;
Cognitive deficit or other physical problem with the potential to interfere with behavioral therapy;
Alcohol or other substance abuse as determined by self-report or prior documentation in the medical record;
Opioid or barbiturate use 10+ days a month;
Unable or unwilling to follow a treatment program that relies on written and audio file materials;
Not having a smartphone.

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

48

Study ID:

NCT05466682

Recruitment Status:

Completed

Sponsor:

NYU Langone Health

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

NYU Langone Health
New York New York, 10016, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

48

Study ID:

NCT05466682

Recruitment Status:

Completed

Sponsor:


NYU Langone Health

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.